ELI LILLY AND COMPANY ADA Update
July 1, 2021
Not for promotional use
1
Introduction
Mike Mason, President, Lilly Diabetes
SURPASS Overview
Jeff Emmick, M.D., Ph.D., Vice President, Lilly
Diabetes Product Development
Early Phase Diabetes
Ruth Gimeno, Ph.D., Vice President, Lilly
Diabetes and Metabolic Research
Q&A
Not for promotional use
2
SAFE HARBOR PROVISION
This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.
For additional information about the factors that may affect the company's business and could cause actual results to differ materially, please see the company's latest Form 10-K, subsequent 10-Q, and 8-K filed with the Securities and Exchange Commission.
The company undertakes no duty to update forward-looking statements
Not for promotional use
2021 LILLY ADA UPDATE | 3 |
MOMENTUM IN DIABETES BUSINESS
SIGNIFICANT GROWTH IN THE PAST DECADE WITH DIVERSE OPPORTUNITIES IN THE FUTURE
2010-2020
GROWTH BEYOND INSULIN
DIABETES WORLDWIDE REVENUE HAS MORE THAN TRIPLED ~$12B
~$4B
2010 | 2020 | |||||||||
® | ® | ® | ® | |||||||
® | ||||||||||
Humalog | Humulin | Trulicity | Jardiance | Basaglar | Other |
2020-2030
DIABETES & RELATED METABOLIC DISORDERS
Trulicity: Additional doses and cardiovascular outcomes reinforce market leadership and are catalysts for continued class growth
Jardiance: Continued market leadership in growing SGLT-2 inhibitor class with potential NILEX opportunities in HFrEF, HFpEF and CKD
Insulin: Connected care potential to improve patient outcomes
Tirzepatide: Potential paradigm changing treatment in type 2 diabetes with expanding NILEX opportunities in obesity and other metabolic disorders
Early-stagepipeline: Opportunities across classes including basal insulin FC, GGG and oral incretins
Note: Jardiance and Basaglar are part of the Boehringer Ingelheim (BI) and Lilly Alliance and BI holds the marketing authorization for Jardiance; NILEX = line extension; HFrEF = heart failure with reduced ejection fraction; HFpEF = heart failure with preserved | 4 |
ejection fraction; CKD = chronic kidney disease; GGG = GIP, GLP-1and Glucagon triple receptor agonist | 2021 LILLY ADA UPDATE |
Not for promotional use |
TIRZEPATIDE SURPASS PROGAM
OVERVIEW & NEXT STEPS
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Eli Lilly and Company published this content on 01 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 July 2021 14:52:25 UTC.
